Neurology: Volume 98, Number 11, March 15, 2022 Exam #2 - Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Disease: CHANCENMO Study
About this course
- Released: 03/15/2022
- Expires: 03/15/2025
Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-ANTIBODY–ASSOCIATED DISEASE: CHANCENMO STUDY
LEARNING OBJECTIVES:
Upon completion of the article by Hummert et al, the participant should be able to:
- Discuss which factors were the most important drivers of direct medical costs among patients with NMO spectrum disorders (NMOSD) and MOG-antibody–associated disease (MOGAD) in this study
- State the proportion of patients with NMOSD or MOGAD that required some type of informal care (e.g., supervision, assistance) in this study
- Identify specific dimensions of the EQ-5D-5L quality of life instrument in which patients with NMOSD or MOGAD were most likely to report slight to extreme problems in this study
CORE COMPETENCIES:
The article by Hummert et al covers the following core competency:- Medical Knowledge
AUTHOR DISCLOSURES:
Refer to Information and Author section available in the Tool Bar for each article.
THIS PAGE IS REQUIRED READING BEFORE BEGINNING ALL ACCME-ACCREDITED COURSES
ACCREDITATION STATEMENT
The American Academy of Neurology Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MISSION STATEMENT/PROGRAM OBJECTIVES
After evaluating a specific article published in Neurology, participants in the CME activity should be able to demonstrate an increase in, or affirmation of, their knowledge of clinical medicine. Participants should be able to evaluate the appropriateness of the clinical information as it applies to the provision of patient care.
PARTICIPANTS
This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.
AMA CREDIT DESIGNATION STATEMENT
The American Academy of Neurology Institute designates this journal-based-CME activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURES
CME Journal Editors: James W.M. Owens, Jr., MD, PhD: Scientific Advisory Boards: Member of data safety monitoring board, RaSURE study, AADi Bioscience, Inc. Funding for travel or speaker honoraria: Honoraria, Program Director, AAN Annual Meeting. Editorial Boards: CME Editor, Neurology and Adam Kelly, MD: Editorial Boards: Neurology, CME editor, ongoing since January 2016. Other activities: Question writing for American Academy of Neurology activities, including Continuum. AAN staff members editing the test (K. Aman Ramm) have no disclosures. All relevant financial relationships have been mitigated.
COMMERCIAL SUPPORT
This CME program receives no commercial support.
